Skip to content
10-K

Annual Report

Coeptis Therapeutics, Inc.

0001683168-22-001616

← back to feed
Filed
Mar 11, 2022 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2021 · Mar 11, 2022 37.97M sh
Stock Repurchased FY 2021 · Dec 31, 2021 $247.17K
Capex FY 2021 · Dec 31, 2021 $0
Capex FY 2021 · Dec 31, 2020 $0
Operating Cash Flow FY 2021 · Dec 31, 2021 −$4.49M
Operating Cash Flow FY 2021 · Dec 31, 2020 −$3.14M
Long Term Debt FY 2021 · Dec 31, 2021 $1.65M
Long Term Debt FY 2021 · Dec 31, 2020 $150K
Stockholders Equity FY 2021 · Dec 31, 2021 $2.35M
Stockholders Equity restated FY 2021 · Dec 31, 2020 −$5.14M
Stockholders Equity restated FY 2021 · Dec 31, 2019 $919.48K
Current Liabilities FY 2021 · Dec 31, 2021 $2.76M
Current Liabilities restated FY 2021 · Dec 31, 2020 $5.28M
Total Liabilities FY 2021 · Dec 31, 2021 $4.41M
Total Liabilities restated FY 2021 · Dec 31, 2020 $5.44M
Current Assets FY 2021 · Dec 31, 2021 $2.18M
Current Assets FY 2021 · Dec 31, 2020 $224.75K
Total Assets FY 2021 · Dec 31, 2021 $6.77M
Total Assets restated FY 2021 · Dec 31, 2020 $300.48K
Sga Expense FY 2021 · Dec 31, 2021 $14.12M
Sga Expense FY 2021 · Dec 31, 2020 $5.77M
Rd Expense FY 2021 · Dec 31, 2021 $0
Rd Expense FY 2021 · Dec 31, 2020 $3.54K
Net Income FY 2021 · Dec 31, 2021 −$13.45M
Net Income FY 2021 · Dec 31, 2020 −$9.16M
Operating Income FY 2021 · Dec 31, 2021 −$14.23M
Operating Income FY 2021 · Dec 31, 2020 −$6.86M
Gross Profit FY 2021 · Dec 31, 2021 $75K
Gross Profit FY 2021 · Dec 31, 2020 −$933.46K
Cost Of Revenue FY 2021 · Dec 31, 2021 $0
Cost Of Revenue FY 2021 · Dec 31, 2020 $964.22K
Revenue FY 2021 · Dec 31, 2021 $75K
Revenue FY 2021 · Dec 31, 2020 $30.76K